 |
 |
 |
|
 |
The U.S healthcare system is under tremendous stress as a result of unsustainable cost pressures, demographic shifts and the advent of new medical technologies. By personalizing medicine through better understanding of the individual we can improve patient care and greatly increase healthcare productivity. MDV funds entrepreneurs and cross-disciplinary teams focused on biomedical breakthroughs, molecular diagnostics and technology platforms that will deliver on this vision. |
|||||||||||||||||||||||||||
 |
Pacific Biosciences' mission is to transform the way humankind acquires, processes, and interprets data from living systems. The company has developed a disruptive technology platform for the real-time detection of biological events at single molecule resolution. Single Molecule Real Time (SMRT™) Biology promises to revolutionize the life sciences by revealing the underlying networks that define living systems. The first application for the SMRT Biology platform is a paradigm changing approach to DNA sequencing. SMRT technology will ultimately make it possible to sequence individual genomes as part of routine medical care. DNA sequencing is expected to be the first of many transformative SMRT Biology applications that will benefit society by driving radical advances in fields such as personalized medicine, agriculture, clean energy, and global health. Founded in 2004.
RainDance's proprietary technology platform delivers exquisite sensitivity and data quality that inspires scientists, researchers and clinicians to rethink the way they design experiments, approach discovery, or conduct clinical diagnostics. The core RainStorm™ technology empowers customers to conduct de novo science in an ultra-high throughput, simple, flexible, and low-cost manner. RainDance's commercial products include instruments and high-value consumables and reagents for sequence enrichment for next-generation sequencing, ultra-deep sequencing, and methylation analysis. Founded in 2004. www.raindancetechnologies.com/
Corventis is a pioneer in wireless cardiovascular solutions. The company's technology provides clinicians with actionable information for early detection of clinical events to support preventative and proactive treatment strategies. Its goal is to usher in a new era of personalized patient care with patient- and physician-friendly solutions that: wirelessly connect clinicians and patients; provide unprecedented visibility into patient health status; deliver exception based, actionable information for detection, prevention and treatment; enable secure access to data anywhere across the globe and generate significant cost savings throughout the healthcare system. Founded 2005.
Navigenics, Inc. specializes in personalized consumer health and wellness services, with the overall goal of improving health outcomes in individuals across the population. Navigenics educates and empowers customers with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact.
On-Q-ity is a second generation diagnostics company transforming cancer treatment through non-invasive diagnostics and monitoring. The company is focused on offering oncologists and their patients more cost-effective, informative and actionable treatment guidance through innovative diagnostics that identify the unique characteristics of an individual's cancer, predict the response to therapy, and monitor the efficacy of treatment. On-Q-ity leverages two core technologies: DNA repair pathway biomarkers to predict treatment response in tissue and blood and microfluidic chip technology to capture, enumerate, and molecularly characterize circulating tumor cells (CTC) from a sample of blood. The company's CTC and biomarker technologies originated from groundbreaking research at Massachusetts General Hospital and the Dana Farber Cancer Institute and MIT, respectively. Founded in May 2009
Tethys Bioscience is dedicated to the discovery, development and commercialization of novel biological markers - biomarkers - that provide a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. Founded in 2002
VitaPath Genetics develops molecular diagnostics to help patients and their doctors correct genetic mutations that can result in serious, but preventable, disease. The company's initial focus is a validated genetic test for spina bifida, a common birth defect that can be avoided with high dose folic acid therapy under the care of a physician.
Adamas is an emerging pharmaceutical company focused on developing small molecule Advantaged Therapeutics to treat neurological and infectious diseases, including influenza A, the cause of the most recent flu pandemic. Adamas' approach to pharmaceutical development is to identify synergistic drug mechanisms that can be developed as optimized combination drug therapies to increase safety, efficacy and compliance, thus improving upon the standard of care.
CardioDx is a molecular diagnostics company that serves cardiologists and their patients by offering clinically validated genomic tests to enhance patient care. These tests will help cardiologists identify patients who will benefit most from advanced cardiovascular therapies and predict risk for developing disease. Founded in 2004.
iRhythm is working to ensure that cardiac rhythm monitoring is accessible and available to many more patients at risk for an abnormal heart rhythm, or an arrhythmia. The company has assembled a multi-disciplinary team to meet this challenge. iRhythm's approach can be traced back to Stanford University's Biodesign Program, where its founder, Uday Kumar MD, worked with two engineers and a business school graduate to understand the unmet clinical needs of patients suffering from arrhythmias. From this collaboration came a clear appreciation that many patients suffering from arrhythmias were simply not being diagnosed and those who were, were being diagnosed in an inefficient and untimely manner.
> See more portfolio companies.
|
|
|
||||||||||||||||||||||||
 
      
|
|||||||||||||||||||||||||||
